Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347
Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 12,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.
"Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies" said Dr Nigel McCracken, Vice President, Translational Medicine. "Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers".
AACR 2015 Abstract
Compound Title Date and Time No. Debio 1143 SMAC mimetic and radiotherapy synergize to Sun, Apr 19, #283 enhance antitumor immunity in lung cancer by 1:00 - 5:00 pm targeting immunosuppressive cells Debio 1143 synergizes with taxanes, Mon, Apr 20, #2529 topoisomerase and bromodomain inhibitors to 1:00 - 5:00 pm inhibit growth of lung adenocarcinoma The IAP inhibitor Debio 1143 reverses Mon, Apr 20, #2700 carboplatin resistance in ovarian cancer cells 1:00 - 5:00 pm by inducing both apoptosis and necroptosis Debio 1347 Characterization of two novel oncogenic Sun, Apr 19, #689 FGFR2 fusions sensitive to the FGFR-selective 1:00 - 5:00 pm inhibitor Debio 1347 in cholangiocarcinoma Formulation switch and pharmacokinetics/ Mon, April 20, Abstract pharmacodynamics of Debio 1347 (CH5183284), a 8:00 - 12:00 am CT228 novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients Additional poster regarding Debio 1347 to be Sun, Apr 19, Abstract presented by Chugai Pharmaceutical, the 1:00 - 5:00 pm #123 originator of the compound: Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1
About Debiopharm International SA
Debiopharm Group(TM) is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information, please visit: http://www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Debiopharm International SA Contact Christelle Tur Communication Coordinator email@example.com Tel: +41(0)21-321-01-11 Additional Media Contacts In London Maitland Martin Barrow firstname.lastname@example.org Tel: +44(0)20-7395-0444 In New York Russo Partners, LLC Marissa Goberdhan Account Executive email@example.com Tel: +1-212-845-4253